- Stocks
- Pharma & Healthcare
- Dr. Reddy's Laboratories
Dr. Reddy's Laboratories share price
NSE: DRREDDYPharma & Healthcare
Dr. Reddy's Laboratories at a glance
Dr. Reddy's Laboratories (NSE: DRREDDY) closed at ₹1,241.20 on 19 Oct 2026, up 0.89% on the day. With a market capitalisation of ₹1,03,600 Cr, it ranks 101st by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.
At its last close the stock traded at 25× trailing earnings, against a return on equity of 11.1% in FY26. Over the past year the share price has fallen 1.8%. Its 52-week range is ₹1,101.00 (23 Jul 2026) to ₹1,414.90 (29 Jun 2026); the last close is 12.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹8,071 Cr (−5.6% year on year) and net profit ₹435 Cr (−69.2%), on a consolidated basis. Promoters held 26.64% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,03,600 CrRank 101 on NSE
- P/E (trailing)
- 25×
- Price to book
- 2.76×FY26
- EPS (TTM)
- ₹38.69to Q1 FY27
- ROE
- 11.1%FY26
- ROCE
- 13.9%FY26
- Debt to equity
- 0.17FY26
- Net profit margin
- 15.7%FY26
- Book value / share
- ₹453.79FY26
- Dividend payout
- 10.6%FY26
- 52-week high
- ₹1,414.9029 Jun 2026
- 52-week low
- ₹1,101.0023 Jul 2026
- 1-year return
- −1.8%
- RSI (14-day)
- 59.4
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.89% | +0.8% | +5.6% | +1.6% | −1.8% |
Dr. Reddy's Laboratories quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8,038 Cr | ₹8,381 Cr | ₹8,506 Cr | ₹8,545 Cr | ₹8,805 Cr | ₹8,727 Cr | ₹7,516 Cr | ₹8,071 Cr |
| Revenue YoY | +16.5% | +15.8% | +20.1% | +11.0% | +9.5% | +4.1% | −11.6% | −5.6% |
| Net profit | ₹1,336 Cr | ₹1,400 Cr | ₹1,581 Cr | ₹1,410 Cr | ₹1,331 Cr | ₹1,187 Cr | ₹217 Cr | ₹435 Cr |
| Net profit YoY | −9.6% | +1.6% | +21.0% | +1.7% | −0.4% | −15.2% | −86.3% | −69.2% |
| Net margin | 16.6% | 16.7% | 18.6% | 16.5% | 15.1% | 13.6% | 2.9% | 5.4% |
| EPS | ₹80.45 | ₹16.97 | ₹19.12 | ₹17.04 | ₹16.18 | ₹14.53 | ₹2.65 | ₹5.33 |
Dr. Reddy's Laboratories financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹19,048 Cr | ₹21,545 Cr | ₹24,670 Cr | ₹28,011 Cr | ₹32,644 Cr | ₹33,700 Cr |
| Operating profit | ₹2,836 Cr | ₹2,991 Cr | ₹6,012 Cr | ₹7,186 Cr | ₹7,658 Cr | ₹5,379 Cr |
| Net profit | ₹1,904 Cr | ₹2,112 Cr | ₹4,470 Cr | ₹5,563 Cr | ₹5,704 Cr | ₹4,144 Cr |
| EPS (₹) | ₹118.00 | ₹132.00 | ₹271.00 | ₹335.00 | ₹68.00 | ₹50.00 |
| Cash from operations | ₹3,570 Cr | ₹2,811 Cr | ₹5,888 Cr | ₹4,543 Cr | ₹4,643 Cr | ₹5,674 Cr |
| Total debt | ₹380 Cr | ₹380 Cr | ₹0 Cr | ₹380 Cr | ₹380 Cr | ₹0 Cr |
| Shareholders' equity | ₹17,642 Cr | ₹19,212 Cr | ₹23,286 Cr | ₹28,255 Cr | ₹33,550 Cr | ₹37,892 Cr |
Dr. Reddy's Laboratories shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 26.64% | 26.64% | 26.64% | 26.64% | 26.63% | 26.64% |
| Foreign institutions | 37.29% | 36.36% | 35.52% | 33.20% | 33.08% | 32.07% |
| Domestic institutions | 25.62% | 26.74% | 27.98% | 30.44% | 30.72% | 31.74% |
| Non-institutions | 10.15% | 10.00% | 9.61% | 9.47% | 9.33% | 9.35% |
Dr. Reddy's Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Dr. Reddy's Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| LAURUSLABSLaurus Labs | ₹2,061.90 | +0.17% | +135.1% | ₹1,11,394 Cr | 124.8 | 8.0% |
| ZYDUSLIFEZydus Lifesciences | ₹1,111.50 | −1.23% | +11.9% | ₹1,10,873 Cr | 22.2 | 18.6% |
| APOLLOHOSPApollo Hospitals Enterprise | ₹7,695.00 | −1.75% | +0.1% | ₹1,10,642 Cr | 57 | 20.5% |
| CIPLACipla | ₹1,324.00 | −0.12% | −15.6% | ₹1,06,959 Cr | 27.5 | 11.3% |
| DRREDDYDr. Reddy's Laboratories | ₹1,241.20 | +0.89% | −1.8% | ₹1,03,600 Cr | 25 | 11.1% |
| AUROPHARMAAurobindo Pharma | ₹1,617.00 | −2.54% | +43.1% | ₹93,039 Cr | 26.8 | 9.2% |
| MANKINDMankind Pharma | ₹2,251.00 | −1.11% | −8.5% | ₹92,965 Cr | 48.7 | 11.7% |
Ask anything about Dr. Reddy's Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against DRREDDY's own history. Try: “Why has DRREDDY moved over the last three months?” · “Backtest a 50-day moving-average crossover on DRREDDY over five years” · “Compare DRREDDY with LAURUSLABS on margins and valuation”
Frequently asked questions about Dr. Reddy's Laboratories
What is the share price of Dr. Reddy's Laboratories today?
Dr. Reddy's Laboratories (NSE: DRREDDY) last closed at ₹1,241.20 on 19 Oct 2026. Its 52-week high is ₹1,414.90 and its 52-week low is ₹1,101.00.
What is the market cap of Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories' market capitalisation is ₹1,03,600 Cr (₹1.04 lakh Cr) at the 19 Oct 2026 close, ranking 101st among the NSE companies Pivot tracks.
What is the P/E ratio of Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories trades at a trailing P/E of 25. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 48.7.
What is the ROE and ROCE of Dr. Reddy's Laboratories?
Return on equity was 11.1% in FY26 and return on capital employed was 13.9% in FY26 (consolidated figures).
Is Dr. Reddy's Laboratories a debt-free company?
No. Dr. Reddy's Laboratories' debt-to-equity ratio was 0.17 in FY26, with total debt of ₹0 Cr.
What were Dr. Reddy's Laboratories' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Dr. Reddy's Laboratories reported revenue of ₹8,071 Cr, −5.6% year on year, and net profit of ₹435 Cr, −69.2% year on year.
How has Dr. Reddy's Laboratories stock performed over the last year?
Dr. Reddy's Laboratories' share price has fallen 1.8% over the past year, +1.6% over three months and +5.6% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Dr. Reddy's Laboratories?
As of 30 Jun 2026: promoters 26.64%, foreign institutions 32.07%, domestic institutions 31.74%, non-institutions 9.35%.
Who are Dr. Reddy's Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Dr. Reddy's Laboratories by market cap are Laurus Labs, Zydus Lifesciences, Apollo Hospitals Enterprise, Cipla, Aurobindo Pharma and Mankind Pharma.
Is Dr. Reddy's Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Dr. Reddy's Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DRREDDY against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text